{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-24-000078","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.723720+00:00","generated_at":"2026-05-31T23:07:09.780718+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GRI Bio regains compliance with Nasdaq continued listing standards","bullets":["Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).","Scheduled hearing before Nasdaq Hearings Panel has been canceled.","Now in compliance with all applicable continued listing standards on Nasdaq Capital Market.","No financial impact or operational changes disclosed; CEO expresses focus on core business."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-24-000078","json":"https://secwatch.observer/filing/0001824293-24-000078.json","markdown":"https://secwatch.observer/filing/0001824293-24-000078.md","text":"https://secwatch.observer/filing/0001824293-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000078/0001824293-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000078/val-20240702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:07:09.780718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}